The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

Hussein Sultan, Takumi Kumai, Toshihiro Nagato, Juan Wu, Andres M. Salazar, Esteban Celis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL) epitopes have long been considered as a simple and cost-effective approach to treat cancer. However, the efficacy of these vaccines in the clinic in patients with measurable disease remains questionable. We believe that the poor performance of peptide vaccines is due to their inability to generate sufficiently large CTL responses that are required to have a positive impact against established tumors. Peptide vaccines to elicit CTLs in the clinic have routinely been administered in the same manner as vaccines designed to induce antibody responses: injected subcutaneously and in many instances using Freund’s adjuvant. We report here that peptide vaccines and poly-ICLC adjuvant administered via the unconventional intravenous route of immunization generate substantially higher CTL responses as compared to conventional subcutaneous injections, resulting in more successful antitumor effects in mice. Furthermore, amphiphilic antigen constructs such as palmitoylated peptides were shown to be better immunogens than long peptide constructs, which now are in vogue in the clinic. The present findings if translated into the clinical setting could help dissipate the wide-spread skepticism of whether peptide vaccines will ever work to treat cancer.

Original languageEnglish (US)
Pages (from-to)455-466
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume68
Issue number3
DOIs
StatePublished - Mar 13 2019

Fingerprint

Cancer Vaccines
Subunit Vaccines
Cytotoxic T-Lymphocytes
Peptides
Vaccines
Neoplasms
Synthetic Vaccines
T-Lymphocyte Epitopes
Freund's Adjuvant
Subcutaneous Injections
Antibody Formation
Immunization
Antigens
Costs and Cost Analysis

Keywords

  • CD8 T cells
  • Melanoma
  • Peptide vaccines
  • Route of injection

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. / Sultan, Hussein; Kumai, Takumi; Nagato, Toshihiro; Wu, Juan; Salazar, Andres M.; Celis, Esteban.

In: Cancer Immunology, Immunotherapy, Vol. 68, No. 3, 13.03.2019, p. 455-466.

Research output: Contribution to journalArticle

Sultan, Hussein ; Kumai, Takumi ; Nagato, Toshihiro ; Wu, Juan ; Salazar, Andres M. ; Celis, Esteban. / The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice. In: Cancer Immunology, Immunotherapy. 2019 ; Vol. 68, No. 3. pp. 455-466.
@article{b70a3e8d8bc54c56ae0d6e31e97d2ab6,
title = "The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice",
abstract = "Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL) epitopes have long been considered as a simple and cost-effective approach to treat cancer. However, the efficacy of these vaccines in the clinic in patients with measurable disease remains questionable. We believe that the poor performance of peptide vaccines is due to their inability to generate sufficiently large CTL responses that are required to have a positive impact against established tumors. Peptide vaccines to elicit CTLs in the clinic have routinely been administered in the same manner as vaccines designed to induce antibody responses: injected subcutaneously and in many instances using Freund’s adjuvant. We report here that peptide vaccines and poly-ICLC adjuvant administered via the unconventional intravenous route of immunization generate substantially higher CTL responses as compared to conventional subcutaneous injections, resulting in more successful antitumor effects in mice. Furthermore, amphiphilic antigen constructs such as palmitoylated peptides were shown to be better immunogens than long peptide constructs, which now are in vogue in the clinic. The present findings if translated into the clinical setting could help dissipate the wide-spread skepticism of whether peptide vaccines will ever work to treat cancer.",
keywords = "CD8 T cells, Melanoma, Peptide vaccines, Route of injection",
author = "Hussein Sultan and Takumi Kumai and Toshihiro Nagato and Juan Wu and Salazar, {Andres M.} and Esteban Celis",
year = "2019",
month = "3",
day = "13",
doi = "10.1007/s00262-018-02294-5",
language = "English (US)",
volume = "68",
pages = "455--466",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "3",

}

TY - JOUR

T1 - The route of administration dictates the immunogenicity of peptide-based cancer vaccines in mice

AU - Sultan, Hussein

AU - Kumai, Takumi

AU - Nagato, Toshihiro

AU - Wu, Juan

AU - Salazar, Andres M.

AU - Celis, Esteban

PY - 2019/3/13

Y1 - 2019/3/13

N2 - Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL) epitopes have long been considered as a simple and cost-effective approach to treat cancer. However, the efficacy of these vaccines in the clinic in patients with measurable disease remains questionable. We believe that the poor performance of peptide vaccines is due to their inability to generate sufficiently large CTL responses that are required to have a positive impact against established tumors. Peptide vaccines to elicit CTLs in the clinic have routinely been administered in the same manner as vaccines designed to induce antibody responses: injected subcutaneously and in many instances using Freund’s adjuvant. We report here that peptide vaccines and poly-ICLC adjuvant administered via the unconventional intravenous route of immunization generate substantially higher CTL responses as compared to conventional subcutaneous injections, resulting in more successful antitumor effects in mice. Furthermore, amphiphilic antigen constructs such as palmitoylated peptides were shown to be better immunogens than long peptide constructs, which now are in vogue in the clinic. The present findings if translated into the clinical setting could help dissipate the wide-spread skepticism of whether peptide vaccines will ever work to treat cancer.

AB - Vaccines consisting of synthetic peptides representing cytotoxic T-lymphocyte (CTL) epitopes have long been considered as a simple and cost-effective approach to treat cancer. However, the efficacy of these vaccines in the clinic in patients with measurable disease remains questionable. We believe that the poor performance of peptide vaccines is due to their inability to generate sufficiently large CTL responses that are required to have a positive impact against established tumors. Peptide vaccines to elicit CTLs in the clinic have routinely been administered in the same manner as vaccines designed to induce antibody responses: injected subcutaneously and in many instances using Freund’s adjuvant. We report here that peptide vaccines and poly-ICLC adjuvant administered via the unconventional intravenous route of immunization generate substantially higher CTL responses as compared to conventional subcutaneous injections, resulting in more successful antitumor effects in mice. Furthermore, amphiphilic antigen constructs such as palmitoylated peptides were shown to be better immunogens than long peptide constructs, which now are in vogue in the clinic. The present findings if translated into the clinical setting could help dissipate the wide-spread skepticism of whether peptide vaccines will ever work to treat cancer.

KW - CD8 T cells

KW - Melanoma

KW - Peptide vaccines

KW - Route of injection

UR - http://www.scopus.com/inward/record.url?scp=85059475916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059475916&partnerID=8YFLogxK

U2 - 10.1007/s00262-018-02294-5

DO - 10.1007/s00262-018-02294-5

M3 - Article

C2 - 30604041

AN - SCOPUS:85059475916

VL - 68

SP - 455

EP - 466

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -